PMID- 22155819
OWN - NLM
STAT- MEDLINE
DCOM- 20120824
LR  - 20240405
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Print)
IS  - 0066-4804 (Linking)
VI  - 56
IP  - 3
DP  - 2012 Mar
TI  - Agreement assessment of tigecycline susceptibilities determined by the disk 
      diffusion and broth microdilution methods among commonly encountered resistant 
      bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan 
      (TIST) study, 2008 to 2010.
PG  - 1414-7
LID - 10.1128/AAC.05879-11 [doi]
AB  - The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, 
      is a nationwide surveillance program designed to longitudinally monitor the in 
      vitro activity of tigecycline against commonly encountered drug-resistant 
      bacteria. This study compared the in vitro activity of tigecycline against 3,014 
      isolates of clinically important drug-resistant bacteria using the standard broth 
      microdilution and disk diffusion methods. Species studied included 
      methicillin-resistant Staphylococcus aureus (MRSA; n = 759), vancomycin-resistant 
      Enterococcus faecium (VRE; n = 191), extended-spectrum beta-lactamase 
      (ESBL)-producing Escherichia coli (n = 602), ESBL-producing Klebsiella pneumoniae 
      (n = 736), and Acinetobacter baumannii (n = 726) that had been collected from 
      patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and 
      inhibition zone diameters were interpreted according to the currently recommended 
      U.S. Food and Drug Administration (FDA) criteria and the European Committee on 
      Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC(90) values of 
      tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. 
      pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 mug/ml, respectively. 
      The total error rates between the two methods using the FDA criteria were high: 
      38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the 
      EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii 
      isolates. The total error rates between these two methods were <5% for MRSA, VRE, 
      and ESBL-producing E. coli. For routine susceptibility testing of ESBL-producing 
      K. pneumoniae and A. baumannii against tigecycline, the broth microdilution 
      method should be used because of the poor correlation of results between these 
      two methods.
FAU - Liu, Jien-Wei
AU  - Liu JW
AD  - Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang 
      Gung Memorial Hospital, Chang Gung University Medical College, Kaohsiung, Taiwan.
FAU - Ko, Wen-Chien
AU  - Ko WC
FAU - Huang, Cheng-Hua
AU  - Huang CH
FAU - Liao, Chun-Hsing
AU  - Liao CH
FAU - Lu, Chin-Te
AU  - Lu CT
FAU - Chuang, Yin-Ching
AU  - Chuang YC
FAU - Tsao, Shih-Ming
AU  - Tsao SM
FAU - Chen, Yao-Shen
AU  - Chen YS
FAU - Liu, Yung-Ching
AU  - Liu YC
FAU - Chen, Wei-Yu
AU  - Chen WY
FAU - Jang, Tsrang-Neng
AU  - Jang TN
FAU - Lin, Hsiu-Chen
AU  - Lin HC
FAU - Chen, Chih-Ming
AU  - Chen CM
FAU - Shi, Zhi-Yuan
AU  - Shi ZY
FAU - Pan, Sung-Ching
AU  - Pan SC
FAU - Yang, Jia-Ling
AU  - Yang JL
FAU - Kung, Hsiang-Chi
AU  - Kung HC
FAU - Liu, Chun-Eng
AU  - Liu CE
FAU - Cheng, Yu-Jen
AU  - Cheng YJ
FAU - Chen, Yen-Hsu
AU  - Chen YH
FAU - Lu, Po-Liang
AU  - Lu PL
FAU - Sun, Wu
AU  - Sun W
FAU - Wang, Lih-Shinn
AU  - Wang LS
FAU - Yu, Kwok-Woon
AU  - Yu KW
FAU - Chiang, Ping-Cherng
AU  - Chiang PC
FAU - Lee, Ming-Hsun
AU  - Lee MH
FAU - Lee, Chun-Ming
AU  - Lee CM
FAU - Hsu, Gwo-Jong
AU  - Hsu GJ
FAU - Hsueh, Po-Ren
AU  - Hsueh PR
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20111212
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Carbapenems)
RN  - 6Q205EH1VU (Vancomycin)
RN  - 70JE2N95KR (Tigecycline)
RN  - EC 3.5.2.6 (beta-Lactamases)
RN  - FYY3R43WGO (Minocycline)
SB  - IM
MH  - Acinetobacter baumannii/drug effects/growth & development
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Carbapenems/pharmacology
MH  - *Drug Resistance, Bacterial
MH  - Enterococcus faecium/drug effects/growth & development/isolation & purification
MH  - Escherichia coli/drug effects/growth & development/isolation & purification
MH  - Gram-Negative Bacteria/*drug effects/growth & development/isolation & 
      purification
MH  - Gram-Positive Bacteria/*drug effects/growth & development/isolation & 
      purification
MH  - Humans
MH  - Klebsiella pneumoniae/drug effects/growth & development/isolation & purification
MH  - Longitudinal Studies
MH  - Methicillin-Resistant Staphylococcus aureus/drug effects/growth & 
      development/isolation & purification
MH  - Microbial Sensitivity Tests
MH  - Minocycline/*analogs & derivatives/pharmacology
MH  - Taiwan
MH  - Tigecycline
MH  - Vancomycin/pharmacology
MH  - beta-Lactamases/biosynthesis
PMC - PMC3294924
EDAT- 2011/12/14 06:00
MHDA- 2012/08/25 06:00
PMCR- 2012/09/01
CRDT- 2011/12/14 06:00
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/08/25 06:00 [medline]
PHST- 2012/09/01 00:00 [pmc-release]
AID - AAC.05879-11 [pii]
AID - 05879-11 [pii]
AID - 10.1128/AAC.05879-11 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 2012 Mar;56(3):1414-7. doi: 10.1128/AAC.05879-11. 
      Epub 2011 Dec 12.